Plasma adiponectin in patients with active, early, and chronic rheumatoid arthritis who are steroid- and disease-modifying antirheumatic drug-naive compared with patients with osteoarthritis and controls

The Journal of Rheumatology, 09/09/2009

Laurberg TB et al. – Both early DMARD-naive and chronic RA were associated with higher plasma adiponectin compared to healthy controls, but lower plasma adiponectin than OA. Adiponectin increased 13% during MTX treatment. In patients with RA and OA body mass index, age, sex, and disease activity measures failed to explain the findings


  • Plasma adiponectin was analyzed with a validated in-house immunoassay
  • Adiponectin was measured in healthy controls (n = 45) and patients with early DMARD-naive RA (n = 40), chronic RA (n = 74), and OA (n = 35)
  • In a subgroup of patients with chronic RA (n = 31), the longitudinal effect of MTX treatment on adiponectin (Week 0 vs Week 28) was investigated


  • Adiponectin differed significantly between healthy controls (mean 4.8 ± SD 2.7 mg/l) and the 3 groups, with 8.9 ± 4.8 mg/l in early RA, 11.6 ± 5.6 mg/l in chronic RA, and 14.1 ± 6.4 mg/l in OA
  • Longitudinally, MTX treatment increased adiponectin significantly from 9.7 ± 4.5 mg/l at week 0 to 11.0 ± 4.5 mg/l at week 28 in chronic RA
  • No correlations to disease activity measures were found

Print Article Summary Cat 2 CME Report